NXTC on Nasdaq

NextCure, Inc.

American pharmaceutical preparations company based in Beltsville. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with CAPRICOR THERAPEUTICS, INC., NewAmsterdam Pharma Co N.V. or Prenetics Global Ltd, or pick any stock.

  • TickerNXTC on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersBeltsville, United States2
  • Incorporated inDE3
  • Business address2850 Quarry Lake Drive, Suite 280, Baltimore, Md 212093
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300Y5PR6RJR1STI242
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 58157722

See how the biggest companies compare on our leaderboards

These statements, and other forward-looking statements, are based on management’s current expectations, estimates, forecasts and projections about our business and industry, are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control, and that may cause our actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. Forward-looking statements contained in this Annual Report should be considered in light of these factors and the factors set forth under “Risk Factor Summary” below and the factors described elsewhere in this Annual Report, including in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These factors, and the other caut…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-184.2%Operating margin5
-163.6%Net margin5
252.6%Revenue growth, 20205
-12.5%Return on equity6
0.01×Debt to equity5
-$52.1MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Research and development100¢$46.6M
  • Interest0¢$183.0K

Out of $22.4M in revenue.5 The company lost money this year.

Financial statements

Revenue75$22.4M in 2020+253% since 2019
0$10.0M$20.0M$30.0M2019: $6.3M$6.3M20192020: $22.4M$22.4M2020+253%
Operating income75-$41.2M in 2020+10% since 2019
-$60.0M-$40.0M-$20.0M02019: -$37.5M-$37.5M20192020: -$41.2M-$41.2M2020+10%
Net income75-$36.6M in 2020+8% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$33.7M-$33.7M20192020: -$36.6M-$36.6M2020+8%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$44.9M$41.5M
General and administrative$12.7M$15.7M
Restructuring and asset impairment charges$2.5M
Total operating expenses$57.6M$59.7M
Loss from operations-$57.6M-$59.7M
Other income, net$1.8M$4.1M
Basic (in dollars per share)-$19.65-$23.88
Diluted (in dollars per share)-$19.65-$23.88
Basic (in shares)2.8M shares2.3M shares
Diluted (in shares)2.8M shares2.3M shares
Net loss-$55.8M-$55.7M
Unrealized gain on marketable securities$17.0K$226.0K
Total comprehensive loss-$55.8M-$55.4M

Compare NextCure, Inc. with another company

Leadership

Who has led NextCure, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Richman2019–now

President

  1. Michael Richman2019–now

Chief financial officer

  1. Steven P. Cobourn2019–now

Chief operating officer

  1. Timothy Mayer2020–now
20202025
Board members and other officers (22)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorStephen G. Webster named Dec 10, 202535

Timeline

  1. May 8, 2019New chief executive Michael Richman becomes CEO11

Filings

220 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 47 major events, 86 insider forms, 26 large holders, 1 private raises, 40 other. The latest 20:

  1. Oct 1, 2026S-4/A EDGAR
  2. Sep 25, 2026425 EDGAR
  3. Sep 25, 20268-K EDGAR
  4. Sep 3, 20268-K EDGAR
  5. Aug 18, 2026S-4 EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Aug 14, 2026SCHEDULE 13G EDGAR
  9. Aug 13, 2026SCHEDULE 13G/A EDGAR
  10. Aug 12, 20264 EDGAR
  11. Aug 12, 2026SCHEDULE 13G EDGAR
  12. Aug 10, 2026425 EDGAR
  13. Aug 6, 202610-Q EDGAR
  14. Aug 6, 20268-K EDGAR
  15. Aug 4, 2026425 EDGAR
  16. Aug 3, 20264 PRIMARY DOCUMENT EDGAR
  17. Jul 29, 20264 PRIMARY DOCUMENT EDGAR
  18. Jul 29, 20263 PRIMARY DOCUMENT EDGAR
  19. Jul 16, 2026425 EDGAR
  20. Jul 14, 2026425 EDGAR

The 220 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 5 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 10, 2026Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.Sale30,000$6.16$184.8KForm 4
Jul 31, 2026ADAR1 Capital Management, LLC10% ownerBuy36,303$4.94$179.3KForm 4
Jul 30, 2026ADAR1 Capital Management, LLC10% ownerBuy292,850$4.93$1.4MForm 4
Jul 29, 2026ADAR1 Capital Management, LLC10% ownerBuy3,410$5.00$17.1KForm 4
Jul 28, 2026ADAR1 Capital Management, LLC10% ownerBuy6,400$4.95$31.7KForm 4
Jul 27, 2026ADAR1 Capital Management, LLC10% ownerBuy7,798$5.00$39.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 12, 2025Raised $21.5 million in a private offering of equity Form D: 12 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 30. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ikarian Capital, LLC288,303$461.3K0.1%+50,000
Adage Capital Partners Gp, L.l.c.277,202$443.5K0.0%New
Sofinnova Investments, Inc.222,654$356.2K0.0%No change
Renaissance Technologies LLC171,202$273.9K0.0%+110,668
Vanguard Capital Management LLC156,842$250.9K0.0%−3,631
Millennium Management LLC88,112$141.0K0.0%New
Boothbay Fund Management, LLC84,687$135.5K0.0%+15,070
Squadron Capital Management LLC64,464$103.1K0.0%−200,536
Verdad Advisers, LP60,451$96.7K0.1%+17,496
Pfizer Inc44,347$73.0K0.0%−109,007
Affinity Asset Advisors, LLC41,960$67.1K0.0%−199,866
BlackRock, Inc.37,348$59.8K0.0%+9,555
Jane Street Group, LLC32,725$52.4K0.0%New
Geode Capital Management, LLC29,905$47.9K0.0%−1,187
Cardiff Park Advisors, LLC21,833$34.9K0.0%No change
Vanguard Fiduciary Trust Co16,134$25.8K0.0%+119
Nomura Asset Management International Inc.12,500$20.0K0.0%New
Diadema Partners LP7,742$12.4K0.0%New
Barclays PLC5,726$9.2K0.0%+100
Persistent Asset Partners Ltd1,981$3.2K0.0%New
Tower Research Capital LLC (TRC)1,738$2.8K0.0%New
UBS Group AG594$9510.0%+256
Northwestern Mutual Wealth Management Co83$1330.0%New
Jpmorgan Chase & Co61$1070.0%No change
Morgan Stanley66$1060.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48